[A23-78] Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V
Last updated 02.11.2023
Project no.: A23-78
Commission: Commission awarded on 31.07.2023 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Kidneys and urinary system
Indication:
Adults with chronic kidney disease
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://dx.doi.org/10.60584/A23-78